This company has been marked as potentially delisted and may not be actively trading. Millendo Therapeutics (MLND) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MLND vs. SBTX, MBX, NLTX, CYBN, BIOA, VIRI, WHWK, AVTE, PYRGF, and OSTXShould you be buying Millendo Therapeutics stock or one of its competitors? The main competitors of Millendo Therapeutics include Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Aerovate Therapeutics (AVTE), PyroGenesis Canada (PYRGF), and OS Therapies (OSTX). Millendo Therapeutics vs. Its Competitors Silverback Therapeutics MBX Biosciences Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics Aerovate Therapeutics PyroGenesis Canada OS Therapies Silverback Therapeutics (NASDAQ:SBTX) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends. Which has more risk & volatility, SBTX or MLND? Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Millendo Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Which has better valuation & earnings, SBTX or MLND? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilverback TherapeuticsN/AN/A-$89.48M-$2.42-6.14Millendo TherapeuticsN/AN/A-$36.41MN/AN/A Do insiders & institutionals hold more shares of SBTX or MLND? 74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer SBTX or MLND? In the previous week, Silverback Therapeutics had 1 more articles in the media than Millendo Therapeutics. MarketBeat recorded 1 mentions for Silverback Therapeutics and 0 mentions for Millendo Therapeutics. Silverback Therapeutics' average media sentiment score of 1.16 beat Millendo Therapeutics' score of 0.00 indicating that Silverback Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Silverback Therapeutics Positive Millendo Therapeutics Neutral Is SBTX or MLND more profitable? Silverback Therapeutics' return on equity of -29.62% beat Millendo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silverback TherapeuticsN/A -29.62% -28.20% Millendo Therapeutics N/A -91.03%-72.44% SummarySilverback Therapeutics beats Millendo Therapeutics on 7 of the 8 factors compared between the two stocks. Get Millendo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLND vs. The Competition Export to ExcelMetricMillendo TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$178.05M$835.01M$5.82B$9.73BDividend YieldN/A4.84%3.84%4.09%P/E RatioN/A1.1731.1525.96Price / SalesN/A26.53475.15122.97Price / CashN/A19.5637.1558.38Price / Book5.256.639.116.39Net Income-$36.41M-$4.94M$3.26B$265.56M Millendo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLNDMillendo TherapeuticsN/A$9.35-0.7%N/A+536.5%$178.05MN/A0.0012SBTXSilverback TherapeuticsN/A$16.38-6.4%N/A+9.0%$590.63MN/A-6.7783Positive NewsHigh Trading VolumeMBXMBX Biosciences2.6402 of 5 stars$12.53+11.3%$37.63+200.3%N/A$418.80MN/A-2.7636NLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-45.0%$191.25MN/A-6.5490High Trading VolumeCYBNCybin2.5222 of 5 stars$7.63+5.1%$85.00+1,014.0%N/A$171.26MN/A-1.7450News CoverageAnalyst RevisionBIOABioAge LabsN/A$4.48+3.2%N/AN/A$155.59M$3.86M0.00N/AVIRIVirios TherapeuticsN/A$4.77-2.5%$5.00+4.8%+2,052.3%$91.86MN/A-17.675WHWKWhitehawk TherapeuticsN/A$1.71+1.2%N/AN/A$79.65M$25.98M-28.5040AVTEAerovate TherapeuticsN/A$7.40-1.2%N/A-88.8%$77.68MN/A-2.4720Gap UpHigh Trading VolumePYRGFPyroGenesis CanadaN/A$0.28+4.2%N/A-65.9%$51.78M$9.14M-4.6090Gap UpOSTXOS Therapies2.25 of 5 stars$1.78+6.6%$18.00+911.2%-40.0%$50.01MN/A-2.07N/AAnalyst ForecastGap Up Related Companies and Tools Related Companies SBTX Alternatives MBX Alternatives NLTX Alternatives CYBN Alternatives BIOA Alternatives VIRI Alternatives WHWK Alternatives AVTE Alternatives PYRGF Alternatives OSTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLND) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access